Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals [version 2; referees: 2 approved]

Ira Mills①, Catherine Sheard②, Meredith Hays③, Kevin Douglas③, Christopher C. Winchester④,⑤, William T. Gattrell⑥,⑦

①PAREXEL International, Hackensack, NJ, 07601, USA
②Department of Archaeology and Anthropology, University of Bristol, Bristol, BS8 1TH, UK
③Department of Medicine, Uniformed Services University, Bethesda, MD, 20814, USA
④School of Medicine, Pharmacy and Health, Durham University, Stockton on Tees, TS17 6BH, UK
⑤Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, OX13 5QJ, UK
⑥Oxford Brookes University, Oxford, OX3 0BP, UK
⑦Ipsen Pharma, Abingdon, OX14 4RL, UK

Abstract

**Background:** In articles reporting randomized controlled trials, professional medical writing support is associated with increased adherence to Consolidated Standards of Reporting Trials (CONSORT). We set out to determine whether professional medical writing support was also associated with improved adherence to CONSORT for Abstracts.

**Methods:** Using data from a previously published cross-sectional study of 463 articles reporting randomized controlled trials published between 2011 and 2014 in five top medical journals, we determined the association between professional medical writing support and CONSORT for Abstracts items using a Wilcoxon rank-sum test.

**Results:** The mean proportion of adherence to CONSORT for Abstracts items reported was similar with and without professional medical writing support (64.3% vs 66.5%, respectively; p=0.30). Professional medical writing support was associated with lower adherence to reporting study setting (relative risk [RR]; 0.40; 95% confidence interval [CI], 0.23–0.70), and higher adherence to disclosing harms/side effects (RR 2.04; 95% CI, 1.37–3.03) and funding source (RR 1.75; 95% CI, 1.18–2.60).

**Conclusions:** Although professional medical writing support was not associated with increased overall adherence to CONSORT for Abstracts, important aspects were improved with professional medical writing support, including reporting of adverse events and funding source. This study identifies areas to consider for improvement.
Corresponding author: Ira Mills (ira.mills@parexel.com)

Author roles: Mills I: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Sheard C: Data Curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing – Review & Editing; Hays M: Data Curation, Investigation, Writing – Review & Editing; Douglas K: Data Curation, Investigation, Methodology, Visualization, Writing – Review & Editing; Winchester CC: Conceptualization, Investigation, Methodology, Visualization, Writing – Review & Editing; Gattrell WT: Conceptualization, Investigation, Methodology, Visualization, Writing – Review & Editing

Competing interests: Mills I is an employee of PAREXEL International. Sheard C, Hays M, and Douglas K have no disclosures to report. Gattrell WT is an employee of Ipsen Biopharma. Winchester CC is an employee and Director of Oxford PharmaGenesis Ltd, and a Director and shareholder of Oxford PharmaGenesis Holdings Ltd.

How to cite this article: Mills I, Sheard C, Hays M et al. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals [version 2; referees: 2 approved] F1000Research 2017, 6:1489 (doi: 10.12688/f1000research.12268.2)

Copyright: © 2017 Mills I et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Grant information: The author(s) declared that no grants were involved in supporting this work.

First published: 16 Aug 2017, 6:1489 (doi: 10.12688/f1000research.12268.1)
Introduction
Prior studies demonstrate low levels of adherence to Consolidated Standards of Reporting Trials (CONSORT) guidelines, as well as CONSORT for Abstracts, in reporting randomized controlled trials (RCTs). Professional medical writing support, correctly acknowledged, is endorsed by Good Publication Practice (GPP3), and its prevalence increased between 2001/2002 and 2009/2010, with a reported doubling to nearly 35% of industry-sponsored studies. Professional medical writing support is associated with increased adherence to CONSORT in articles reporting RCTs; in a sample of open-access journals, the number of articles that completely reported ≥50% of the studied CONSORT items was significantly higher with professional medical writing support (39%) than without professional medical writing support (21%; p<0.05).

The purpose of this study was to determine whether professional medical writing support was also associated with improved adherence to CONSORT for Abstracts by analyzing a published dataset from five high-impact general medical journals with overall variable and incomplete adherence.

Methods
We examined data from a published cross-sectional study of 463 articles reporting RCTs. The RCTs were published between 2011 and 2014 in five top medical journals: The New England Journal of Medicine, Annals of Internal Medicine, The Lancet, The BMJ, and JAMA. We determined the association between professional medical writing support and the reporting of CONSORT for Abstracts items (Table 1) using a Wilcoxon rank-sum test. One author (CS), who was blinded to the CONSORT for Abstracts scores using de-identified original dataset outputs, identified articles as being prepared with professional medical writing support using automated searching of the full text article followed by manual review if they acknowledged the involvement of one of the following: medical writer, medical writing, writing services, writing assistance, editorial assistance, or editorial support. The context of these terms was also examined.

Mean proportions of CONSORT for Abstract adherence with and without professional medical writing support was compared using a Wilcoxon rank-sum test, and then tested with additional effect of variable journal adherence using an analysis of variance (ANOVA).

Results
From the original published dataset of 463 abstracts from RCTs reported in five journals, acknowledged professional medical writing support was observed in 66 articles (14.3%). Two articles identified in the automated search were excluded on manual review, one of which stated, “there was no writing assistance from anyone who is not listed as an author,” and the other, “the Writing committee drafted the report… without editorial assistance.” The mean proportion of CONSORT for Abstracts items reported in articles with (n=66) and without (n=397) professional medical writing support was 64.3% versus 66.5%, respectively; p=0.3044 (Wilcoxon rank-sum test). This difference remained nonsignificant when journal variation in CONSORT for Abstracts adherence was considered (ANOVA, p=0.1347). Overall, reporting of the individual CONSORT for Abstracts items was similar with and without professional medical writing support (RR 0.97; 95% CI, 0.88–1.07) (Figure 1). However, a lower rate of reporting the study setting (item 4) was observed in articles with professional medical writing support (RR 0.40; 95% CI, 0.23–0.70). Conversely, professional medical writing support was associated with higher adherence to reporting both harms and side effects (item 16) (RR 2.04; 95% CI, 1.37–3.03) and source of funding (item 19) (RR 1.75; 95% CI, 1.18–2.60).

Discussion
Although professional medical writing support was not associated with increased overall adherence to CONSORT for Abstracts, important aspects were improved with professional medical writing support, including reporting of adverse events and funding source. These data confirm prior evidence showing that professional medical writing support is associated with improved safety reporting, and serve to support the important role of professional medical writers in promoting adherence to Medical Publishing Insights & Practices recommendations to improve adverse event reporting in clinical trial publications. Reporting of funding source was also improved with professional medical writing support, most likely reflecting the emphasis placed on transparency about funding by GPP3 guidelines. In articles with professional medical writing support, we observed 100% adherence for other important CONSORT for Abstract items, including reporting of the clinical trials registration number (item 18), vital for transparency and study tracking, which has recently been automated using technology such as the TrialsTracker.

In this post hoc analysis, there was substantial risk of false positives given that separate confidence intervals were computed for 19 different CONSORT items. However, the p value for...
Table 1. CONSORT for Abstracts checklist items⁹, with descriptors by Hays et al.⁹ as used for this post hoc analysis.

| CONSORT for Abstracts items | Yes | No |
|----------------------------|-----|----|
| **Abstract evaluation checklist** |     |    |
| **Title**                  |     |    |
| 1. Do the authors state explicitly in the title that the participants were **randomly assigned** to their comparison groups? |   | |
| **Trial design**           |     |    |
| 2. Is the type of randomized controlled trial described (e.g. parallel group, cluster randomized, crossover, factorial, superiority, noninferiority, or some other combination of these)? |   | |
| **Methods**                |     |    |
| **Participants**           |     |    |
| 3. Is there a clear description of the eligibility criteria for trial participants (e.g. inclusion and/or exclusion criteria)? Can the reader reasonably describe the study population and assess the generalizability of the trial? |   | |
| 4. Is there a clear description of the setting of the participants studied (i.e. primary/secondary/tertiary care center, government health clinic, community clinic; level of care provided at study site)? This does not have to mention geographic setting (i.e. country). |   | |
| **Intervention**           |     |    |
| 5. Are essential features of the experimental and comparison interventions described, including details about the interventions (e.g. dose, route of administration, duration of administration, surgical procedure, or manufacturer of inserted device)? The abstract must give details about the intervention to help the reader quickly assess the validity of the study. |   | |
| **Objective**              |     |    |
| 6. Is there a clear statement of the specific objective or hypothesis addressed in the trial? Either a clear statement is made or it is not. |   | |
| **Outcome**                |     |    |
| 7. Do the authors explicitly state the **primary** or **main** outcome for the trial and when it was assessed (e.g. the time frame over which it was measured)? |   | |
| **Randomization**          |     |    |
| 8. Do the authors clearly describe the method for **random sequence generation** in assigning participants to interventions? |   | |
| 9. Do the authors clearly describe the method of **allocation concealment**? |   | |
| **Blinding**               |     |    |
| 10. Is the study “blinded” or “masked” to group assignment? |   | |
| 11. Does the abstract specify who was “blinded” or “masked” (e.g. participants, caregivers, those assessing outcomes, data analysts)? |   | |
| **Results**                |     |    |
| 12. Is the number of participants **randomized** to each group stated? |   | |
| 13. Is the number of participants **analyzed** for each group stated? |   | |
| 14. Is the primary outcome result for each group stated? |   | |
| 15. Is there an estimated effect size and precision (i.e. are confidence intervals given)? |   | |
| 16. Is there an explicit statement of harms or side effects, or an explicit statement of their absence? Harms and side effects do not have to be specifically labeled as such. Abstracts can satisfy this criterion by stating specific outcomes that are not the primary objective of the study and could reasonably be considered a harm or side effect of the intervention or treatment. This is typically stated in the last sentence of the results. |   | |
| **Conclusions**            |     |    |
| 17. Is the interpretation of the trial clearly stated? |   | |
| **Registration**           |     |    |
| 18. Is the trial registration number and trial register stated? |   | |
| **Funding**                |     |    |
| 19. Is the source of funding for the trial stated? |   | |
Figure 1. Reporting of CONSORT for Abstracts items in articles with and without acknowledged professional medical writing support. CONSORT, Consolidated Standards of Reporting Trials; PMWS, professional medical writing support. Significant associations are shaded.

| CONSORT for Abstracts item | Events/total with PMWS | Events/total without PMWS | Relative risk | Favors no PMWS | Favors PMWS |
|---------------------------|------------------------|---------------------------|--------------|----------------|-------------|
| 1. Randomly assigned      | 36/66                  | 331/397                   | 0.65         |                |             |
| 2. Type of trial          | 26/66                  | 208/397                   | 0.75         |                |             |
| 3. Eligibility criteria   | 48/66                  | 303/397                   | 0.95         |                |             |
| 4. Setting                | 17/66                  | 253/397                   | 0.40         |                |             |
| 5. Experimental intervention | 60/66              | 341/397                   | 1.06         |                |             |
| 6. Specific objective/hypothesis | 63/66          | 380/397                   | 1.00         |                |             |
| 7. Primary outcome        | 63/66                  | 356/397                   | 1.06         |                |             |
| 8. Random sequence generation | 13/66              | 73/397                    | 1.07         |                |             |
| 9. Allocation concealment | 4/66                   | 32/397                    | 0.75         |                |             |
| 10/11. If blinded, who?   | 16/43                  | 120/185                   | 0.57         |                |             |
| 12. Number randomized     | 29/66                  | 251/397                   | 0.69         |                |             |
| 13. Number analyzed       | 30/66                  | 172/397                   | 1.05         |                |             |
| 14. Primary outcome per group | 56/66             | 329/397                   | 1.02         |                |             |
| 15. Effect size           | 43/66                  | 334/397                   | 0.77         |                |             |
| 16. Harms or side effects | 58/66                  | 171/397                   | 2.04         |                |             |
| 17. Interpretation        | 66/66                  | 393/397                   | 1.01         |                |             |
| 18. Trial registration numbers | 66/66             | 378/397                   | 1.05         |                |             |
| 19. Source of funding     | 55/66                  | 189/397                   | 1.75         |                |             |

Overall 749/1165 4614/6934 0.97 0.25 0.50 1.0 2.0

setting (item 4) was 0.0010, for harms or side effects (item 16) was 0.0004, and for source of funding (item 19) was 0.0055; the first two survive a Bonferroni correction, which would conservatively demand that p<0.0026, and all three pass the less stringent Benjamini-Hochberg procedure. Nevertheless, we were disappointed to see that professional medical writing support was not associated with improvements in reporting of other CONSORT for Abstract items, including specification in the title of the design of the study (item 2) and that it was randomized (item 1), and reporting of the numbers randomized and analyzed (items 12 and 13). Indeed, professional medical writing support was actually associated with worse reporting of one item, study setting (item 4) which may be explained by a lack of prioritization by professional medical writers within the constraints of abstract word count limitations. These areas represent clear areas in which professional medical writers can help further improve the reporting of clinical trials in the abstracts of journal articles. The relatively small number of studies with professional medical writing support is this dataset (n=66) did not allow for further exploration of these data (e.g. type of funding, trial phase, institutions where performed). It would be of interest to determine if similar trends are observed in separate studies of CONSORT for Abstracts adherence.

Although this was a post-hoc analysis, it has the advantage that CONSORT for Abstracts adherence was assessed before our study question was posed. Additionally, the presence of professional medical writing support was assigned by an assessor who was blinded to the CONSORT for Abstracts score. However, in the original study, inter-rater agreement for scoring was 84%, which is suboptimal. Furthermore, the original dataset was limited to a sample of high-impact journals, and so may not be generalizable to the biomedical literature as a whole. Indeed, in this dataset of high-impact journals, adherence to CONSORT for Abstracts is likely to have been influenced by the journal’s in-house scientific editing; consequently, the impact of professional medical writing support on adherence to CONSORT for Abstracts may be greater in journals without professional in-house editing. These data were potentially confounded by funding source; because professional medical writing support is typically restricted to industry-funded studies, it is possible that the review processes followed by industry, rather than professional medical writing support per se, caused the improvements in reporting that we observed. However, in industry-funded articles, professional medical writing support was associated with a greater than two-fold increase in ≥50% adherence to CONSORT items studied compared with industry-funded articles prepared without this support (38% vs 18%, p<0.05). In addition, industry funding alone had no impact on the quality of CONSORT reporting in the absence of professional medical writing support. Nevertheless, it can be difficult to correctly ascribe the role of the funder from the details provided in manuscripts as, for example, investigator-led studies typically undergo a different review process to those conducted with full industry support. Finally, although Good Publication
Practice guidelines (GPP3) encourage transparency of professional medical writing support, it remains possible that it was not consistently acknowledged in the studied dataset. In a systematic review of the medical literature, the prevalence of ghostwriting was found to be approximately 5%. Any unacknowledged professional medical writing support would tend towards the null hypothesis enhancing the confidence in the observed statistical differences.

In summary, although professional medical writing support was not associated with increased overall adherence to CONSORT for Abstracts, important aspects were improved with professional medical writing support, including reporting of adverse events and funding source. Ensuring adherence to reporting guidelines is a complex task, so we believe that there is a role for reporting professionals such as professional medical writers to work with authors and journals, to provide training, writing and reviewing, and thereby improve the quality of reporting of clinical trials.

Data availability
Dataset 1: Dataset for reporting of CONSORT for Abstracts items in articles with and without acknowledged professional medical writing support. Dataset used per Hays et al.9

References
1. Hopewell S, Dutton S, Yu LM, et al.: The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010; 340: c278. PubMed Abstract | Publisher Full Text | Free Full Text
2. Plint AC, Moher D, Morrison A, et al.: Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006; 185(6): 263–267. PubMed Abstract
3. Gattrell WT, Hopewell S, Young K, et al.: Assessment of adherence to the CONSORT statement for quality of reports on randomised controlled trial abstracts from four high-impact general medical journals. Trials. 2012; 13: 77. PubMed Abstract | Publisher Full Text | Free Full Text
4. Hopewell S, Ravaud P, Baron G, et al.: Effect of editors’ implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ 2012; 344: e4178. PubMed Abstract | Publisher Full Text | Free Full Text
5. Battistelli WP, Wager E, Baltzer L, et al.: Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015; 163(6): 461–464. PubMed Abstract | Publisher Full Text
6. Kim MR, Nilsen J, Smith G, et al.: Trends in medical writing acknowledgment in medical journals over the last decade. Curr Med Res Opin. 2011; 27(51): S13. Reference Source
7. Gattrell WT, Hopewell S, Young K, et al.: Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open 2016; 6(2): e010329. PubMed Abstract | Publisher Full Text | Free Full Text
8. Gattrell W, Hopewell S, Young K, et al.: Professional medical writing support improves the quality of reporting of randomized controlled trials. Curr Med Res Opin. 2015; 31(1): 520. Reference Source
9. Hays M, Andrews M, Wilson R, et al.: Reporting quality of randomised controlled trial abstracts among high-impact general medical journals: a review and analysis. BMJ Open. 2016; 6(7): e011082. PubMed Abstract | Publisher Full Text | Free Full Text
10. Hopewell S, Clarke M, Moher D, et al.: CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1): e20. PubMed Abstract | Publisher Full Text | Free Full Text
11. Nakazawa M: fmsb:Functions for medical statistics book with some demographic data. R package version 0.5.2. Accessed January 6, 2017. Reference Source
12. R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Accessed January 6, 2017. Reference Source
13. Jüttner E, Unterberg A, Woitzik J, et al.: Hemorragic necrotomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med. 2014; 370(12): 1091–1100. PubMed Abstract | Publisher Full Text
14. PROVE Network Investigators for the Clinical Trial Network of the European Society of Anaesthesiology, Hemmes SN, Gama de Abreu M, et al.: High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. Lancet. 2014; 384(9942): 495–503. PubMed Abstract | Publisher Full Text
15. Jacobs A: Adherence to the CONSORT guideline in papers written by professional medical writers. The Write Stuff 2010; 19: 196–200. Reference Source
16. Lineberry N, Berlin JA, Mansi B, et al.: Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ 2016; 355: h5978. PubMed Abstract | Publisher Full Text
17. Graf C, Battistelli WP, Bridges D, et al.: Research Methods & Reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009; 339: b3330. PubMed Abstract | Publisher Full Text
18. Powell-Smith A, Goldacre B: The TrialsTracker: Automated ongoing monitoring

Competing interests
Mills J is an employee of PAREXEL International. Sheard C, Hays M, and Douglas K have no disclosures to report. Gattrell WT is an employee of Ipsen Biopharma. Winchester CC is an employee and Director of Oxford PharmaGenesis Ltd, and a Director and shareholder of Oxford PharmaGenesis Holdings Ltd.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Acknowledgments
The authors wish to acknowledge Ronald Gruber, M.S, M.L.S, of QWKINSIGHTS, New York, NY, for early support in the design and conception of this study, and Lindy Dunlop and Megan Misukonis of PAREXEL for editorial assistance.

This study was presented at the 13th Annual Meeting of ISMPP, May 1–3, 2017, National Harbor, MD, USA.
of failure to share clinical trial results by all major companies and research institutions [version 1; referees: 2 approved]. F1000Rev. 2016; 6: 2629.

19. Wager E, Woolley K, Adshead V, et al.: Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey. BMJ Open. 2014; 4(4): e004780.

20. Lundh A, Sismondo S, Lexchin J, et al.: Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12: MR000033.

21. Battisti WP, Wager E, Baltzer L, et al.: Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015; 163(6): 461–464.

22. Stretton S: Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literature. BMJ Open. 2014; 4(7): e004777.

23. Mills I, Sheard C, Hays M, et al.: Dataset 1 in: Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017.

Data Source
Open Peer Review

Current Referee Status:  ✔  ✔

Version 2

Referee Report 22 September 2017
doi:10.5256/f1000research.13720.r25988

✔ Ana Marušić
Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia

The authors have addressed my concerns and comments. Although the information presented is rather obvious and based on a previous study, it is important evidence in the field and is suitable for indexing as a research note.

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Dissemination bias, publication integrity

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Referee Report 23 August 2017
doi:10.5256/f1000research.13282.r25067

✔ Jackie M. Marchington
Caudex, Oxford, UK

I have no further comments. Thank you.

**Competing Interests:** As previously stated.

**Referee Expertise:** Professional medical writing, publication ethics

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This is a subanalysis of a previous study detailing the completeness of clinical study reporting in abstracts according to the CONSORT for abstracts checklist. The original publication was restricted to a sample of clinical trial publications in 5 high-ranking general medical journals. This subanalysis investigated differences in adherence to CONSORT for abstracts between papers with or without acknowledged professional medical writing support.

With respect to the co-authors’ previous study, citation of the full paper (ref 8) is sufficient. Citing the poster of the same study is not necessary (ref 7).

Regarding the methods, it is not clear how automated searching would have identified the presence of professional medical writing support. In this reviewer's experience, that has always required retrieval of the full text article. If the automated search was performed on each full text article, I think it would be clearer to state this.

In the discussion, the authors point out funding source as a potential confounder of their results. It would perhaps be of interest to examine industry-funded studies written up without acknowledged professional medical writing support as an additional comparator group to determine whether industry funding was driving differences in CONSORT adherence.

I also have a niggling concern that although GPP3 encourages transparency around the involvement of non-author contributors such as professional medical writers in industry-funded publications, there may be papers in this cohort that used unacknowledged medical writers, papers where a professional writer was included as an author, so not acknowledged as such, or non-industry funded papers where the authors used institutional editorial/writing resource that is not acknowledged. Perhaps the authors could comment on this potential limitation in the discussion.

Although this is a fairly straightforward subanalysis of a previous study, I think it makes an important contribution to the evidence base about the role of professional medical writers, even though the findings are neutral in terms of adherence to CONSORT for abstracts.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** I work for a company that provides professional medical writing services to pharmaceutical and biotechnology clients. I am active in national and international not-for-profit associations that encourage ethical medical writing practices.

**Referee Expertise:** Professional medical writing, publication ethics

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Author Response 11 Sep 2017**

Ira Mills, PAREXEL, USA

We thank Jackie Marchington for her insight and providing suggestions to improve our paper.

Although Good Publication Practice guidelines (GPP3) encourage transparency of professional medical writing support, it remains possible that professional medical writing support was not consistently acknowledged in the studied dataset, and cited evidence in the literature of its prevalence. Any unacknowledged professional medical writing support would tend towards the null hypothesis enhancing the confidence in the observed statistical differences.

As noted by the referee, we have pointed out funding source as a potential confounder of the results and provided discussion as to some of these considerations. The relatively low number of articles with acknowledged professional medical writing support did not allow us to conduct an analysis of professional medical writing support with and without industry support with any statistical validity.

In our paper to support cited information, we have listed both reference 7 (full publication) and reference 8 (corresponding abstract for a prior congress presentation) as the abstract reported p values not found in the full publication. We have swapped the order of the references to have the full publication cited first.

**Competing Interests:** No competing interests were disclosed.

---

**Referee Report 17 August 2017**

doi:10.5256/f1000research.13282.r25066

**Ana Marušić**
Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia

This study presents secondary analysis of a study of adherence to CONSORT reporting guidelines for Abstracts. While the original study (Hays et al, 2016) looked at this adherence in a sample of abstracts from several high-profile medical journals, this study performed a subgroup analysis, looking at whether the mention of professional writing assistance was associated with the score for different items on the
reporting checklist. The study is thus quite methodologically biased, and it is not clear whether the observed differences are real, or random. For example, the finding that the acknowledgment of professional writing assistance decreases the frequency of adequately reporting the setting of the study is difficult to explain. The potential randomness of the significant findings should be addressed in the Discussion section.

Making a publication out of the original publication by looking at a single characteristic does not really warrant the publication of the submitted manuscript. It would be preferable if other characteristics were explored in relation to reporting completeness in abstracts, such as the type of funding, phase of the trial, institutions where trials were performed.

The manuscript is well written and structured, and there are no major comments or suggestions for improvement except the conceptual one described above. In the Methods section, the extraction of data for this study is not fully explained - how many experts extracted the data, how were different terms in the statements on writing assistance interpreted and categorized, etc.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
No

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Dissemination bias, publication integrity

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

Author Response 11 Sep 2017

Ira Mills, PAREXEL, USA

We thank Ana Marušić for her insight and providing suggestions to improve our paper.

We feel that the data described herein fulfill the criteria for publication as a “Research Note” in F1000 Research, designed to report “single-finding papers that can be reported with one or two
illustrations.” Our intention was to conduct a post hoc analysis to specifically examine the role of professional medical writing support on CONSORT adherence as previously described by two of the authors.

In the discussion, we acknowledge that there was substantial risk of false positives given that separate confidence intervals were computed for 19 different CONSORT items. However, the p value for setting (item 4) was 0.0010, for harms or side effects (item 16) was 0.0004, and for source of funding (item 19) was 0.0055; the first two survive a Bonferroni correction, which would conservatively demand that p<0.0026, and all three pass the less stringent Benjamini-Hochberg procedure.

We now include a note in the discussion that the limited number of articles with acknowledged professional medical writing support did not allow further exploration of the results (e.g. type of funding, trial phase, institutions where performed) and also mention that it would be of interest to examine whether similar trends are observed in separate studies of CONSORT for Abstracts.

As described in the original submission, one author performed the data extraction conducting a blinded automated search per the defined terms followed by reexamining for context. We note two articles that were excluded from the analysis by manual review and provide rationale. In one case there was no writing assistance from anyone not listed as an author and in the second case the “Writing committee drafted the report…without editorial assistance.” We have made it clear that this was performed using the full text articles.

**Competing Interests:** No competing interests were disclosed.